MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

GW-1100

CAS No. : 306974-70-9

MCE 站：GW-1100

产品活性：GW-1100是选择性的 GPR40 拮抗剂，pIC₅₀为6.9。

研究领域：GPCR/G Protein

作用靶点：GPR40

In Vitro: GW-1100 (GW1100) dose dependently inhibits GPR40-mediated Ca²⁺ elevations stimulated by GW9508 and linoleic acid (pIC₅₀ values of 5.99±0.03 and 5.99±0.06, respectively). GW-1100 at a concentration of 1 μM produces a significant rightward shift in the concentration-response curve to GW9508 (pEC₅₀=7.17±0.08 in the absence and pEC₅₀=6.79±0.09 in the presence of 1 μM GW-1100; P<0.05; n=3). At concentrations of GW-1100 of 3 μM and higher a significant decrease in the maximal response is observed with a continuing rightward shift in the pEC₅₀ response. GW-1100 (GW1100) reduces FFAR1 ligand-induced intracellular calcium in CHO-K1/bFFAR1 cells and neutrophils. CHO-K1/bFFAR1 cells are incubated for 15 min with 10 μM GW1100 or vehicle (0.1% DMSO) and then stimulated with vehicle, oleic acid, linoleic acid or GW9508. GW-1100 significantly reduces the increase in intracellular calcium induced by 300 μM oleic acid (AUC_{(60-150 s)}, p<0.05), 100 μM linoleic acid (AUC_{(60-150 s)}, p<0.05) and 10 μM GW9508 (AUC_{(60-150 s)}, p<0.05).

In Vivo: The intracerebroventricular injection of DHA (50 ?g) and GW9508 (1.0 ?g), a GPR40-selective agonist, significantly reduces mechanical allodynia and thermal hyperalgesia at day 7, but not at day 1, after CFA injection. These effects are inhibited by intracerebroventricular pretreatment with GW-1100 (10 ?g), a GPR40 antagonist.

相关产品：Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  GW9508  |  DC260126  |  Vincamine  |  AM-4668  |  AS2034178 free base  |  MEDICA16  |  AP5

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。